Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$64.63 USD
+0.28 (0.44%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $64.52 -0.11 (-0.17%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.63 USD
+0.28 (0.44%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $64.52 -0.11 (-0.17%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Akero (AKRO) Slumps 63% on Mixed Results From NASH Study
by Zacks Equity Research
Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.
Madrigal (MDGL) to Raise Capital Via Public Offering of $500M
by Zacks Equity Research
Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the United States.
Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA
by Zacks Equity Research
Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.
Ligand (LGND) Up 4% on Raised '23 EPS, Beats on Q2 Earnings
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports second-quarter results as earnings beat the estimates, but sales miss the mark. Management raises the 2023 financial outlook.
Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Intercept (ICPT) to Restructure Operations, Cut Workforce
by Zacks Equity Research
Intercept (ICPT) looks to restructure operations, discontinue all NASH-related investments and reduce its workforce by one-third.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days
by Zacks Equity Research
Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.
Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation
by Zacks Equity Research
Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.
Intercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment
by Zacks Equity Research
Intercept (ICPT) falls 14.7% a couple of days before the scheduled GIDAC meeting to review its NASH treatment on concerns of adverse events.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study
by Zacks Equity Research
A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.
Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
by Zacks Equity Research
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
Viking (VKTX) Announces Clinical Data for Metabolic Disorders
by Zacks Equity Research
Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.
Intercept (ICPT) Stock Down on FDA Committee Update on NDA
by Zacks Equity Research
Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.
Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months
by Zacks Equity Research
Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.
Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.
Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal
by Zacks Equity Research
Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.
Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study
by Zacks Equity Research
Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.
Viking Therapeutics, Inc. (VKTX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised
by Zacks Equity Research
Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.
Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why
by Zacks Equity Research
Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.